
Worried about recent rise in COVID-19 cases? Here's how to protect yourself without getting a jab
Amidst rising COVID-19 cases in Asia, Yale University researchers have discovered that nasal vaccine boosters offer a safer and more targeted protection against respiratory diseases like COVID-19. The 'prime and spike' approach, combining traditional shots with nasal boosters containing spike proteins, triggers strong immune defenses in the respiratory tract, potentially preventing infection at the point of entry.
Tired of too many ads?
Remove Ads
How are nasal vaccines different from traditional ones
How do nasal vaccines work?
Tired of too many ads?
Remove Ads
In recent weeks, COVID-19 cases have been rising across Asia, with notable surges in Hong Kong, Singapore, and Thailand. In India, the Union Health Ministry reported 257 active cases as of Monday, May 19. Authorities remain on alert, particularly due to the global spread of the JN.1 variant , a sublineage of Omicron. While vaccines played a vital role in curbing the virus during the pandemic, researchers have now identified a promising alternative: a nasal vaccine. This new approach could prove to be safer, more effective, and better at blocking the virus at its primary entry point—the nose.A new study by Yale University researchers suggests that nasal vaccine boosters may provide safer and more targeted protection against respiratory illnesses like COVID-19—without relying on traditional immune-boosting additives. The findings were published in the journal Nature Immunology.While most vaccines and boosters are delivered through injections into muscle tissue, typically in the upper arm, respiratory diseases such as COVID-19 may require protection at the virus's primary entry point: the respiratory tract.'Our study shows how a simple viral protein antigen can boost respiratory tract immune responses against viruses,' said Akiko Iwasaki, Sterling Professor of Immunobiology at Yale School of Medicine (YSM) and senior author of the study. 'These data imply that viral proteins in nasal spray may be used as a safe way to promote antiviral immunity at the site of viral entry.'To explore how nasal vaccines work, researchers first gave mice a traditional mRNA COVID-19 vaccine via intramuscular injection. Later, they administered a booster dose through the nose. Their goal was to study the effectiveness of nasal boosters that don't include adjuvants—special ingredients used in some vaccines to enhance and prolong immune responses. While adjuvants can boost immunity, they may also cause side effects such as inflammation and facial nerve swelling.'We call this vaccine strategy 'prime and spike', which is where the mice were intramuscularly primed with mRNA vaccines followed by a nasal boosting with unadjuvanted spike protein,' Dong-il Kwon, a postdoctoral fellow in Yale's Department of Immunobiology, said in a statement.The scientists found that only the nasal booster triggered a strong local immune response. Other boosters, including intramuscular injection, didn't produce much IgA or activate immune cells in the lungs of the mice. When the researchers gave the mice a second nasal booster, their IgA levels increased even more in both the lungs and nasal passages.'These findings help explain why nasal boosters do not require adjuvants to induce robust mucosal immunity at the respiratory mucosa and can be used to design safe and effective vaccines against respiratory virus pathogens,' Kwon added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


India Today
39 minutes ago
- India Today
RT-PCR test mandatory for ministers before meeting PM amid Covid surge: Sources
An RT-PCR test has been made compulsory for ministers meeting Prime Minister Narendra Modi, as active Covid-19 cases in the country crossed the 7,000 mark today, sources told India Today 70 BJP functionaries from Delhi -- including the Delhi Chief Minister, all seven MPs, and MLAs -- who are scheduled to meet Prime Minister Modi at his residence this evening, will undergo an RT-PCR test, sources the BJP's victory in the Delhi Assembly polls, PM Modi has invited all state party leaders for dinner at 7:30 pm. According to the official statement released by the Union Health Ministry on Wednesday, the country has witnessed 306 fresh cases and six deaths in the past 24 three deaths have been recorded in Kerala, Maharashtra (1) and Karnataka (2) are the only states to have reported the remaining deaths during the same has seen the highest single-day jump, reporting 170 fresh cases. Meanwhile, Gujarat has recorded 114 new infections and 1,223 active cases, followed by Karnataka, which has logged 100 new cases, as per the recorded 66 fresh cases in the last 24 hours and the city's total caseload reached 757, the Health Ministry overall picture is no different, with Kerala leading the tally as its total active cases crossed the 2,000 mark, followed by Gujarat, West Bengal and a rise in Covid cases, the Centre has launched mock drills across the nation to assess hospital preparedness. It has further directed states to ensure an adequate supply of oxygen, isolation beds, ventilators, and essential officials maintain that most cases are mild in Watch


India Today
39 minutes ago
- India Today
Covid-19 claims 6 lives in last 24 hours, active tally breaches 7,000 mark
Covid-19 cases in India continued to witness a gradual uptick, with 306 fresh infections being reported from across the country in the past 24 hours and active tally surging to 7,121, according to official data shared by the Union Health Ministry on Wednesday. 6 deaths, one in Maharashtra, 3 in Kerala and 2 in Karnataka, were also reported during the same reported the highest single-day jump with 170 new Covid cases, pushing its active tally to 2,223, followed by Gujarat with 114 fresh infections and 1,223 active cases. Meanwhile, Karnataka logged 100 new cases and a total of 459 active infections, the data logged 66 infections in the last 24 hours and the city's total caseload reached 757, the Health Ministry said. An 87-year-old female, along with two males (69, 78), all battling comorbidities, died of Covid-19 in Kerala. A 51-year-old woman with hypertension, Type 2 diabetes and a 79-year-old man with hypertension succumbed to the Maharashtra, a 43-year-old male with breathlessness, abdominal pain, distress, tachycardia and cyanosis died due to Covid, officials reported its first Covid death on Tuesday (June 10) as a 44-year-old man, who had tested positive for the infection, died in the state capital Ranchi, officials said. He was undergoing treatment at the Rajendra Institute of Medical Sciences (RIMS) in the capital patient was suffering from multiple diseases and also tested positive for Covid-19," Ranchi civil surgeon Prabhat Kumar told news agency PTI. According to a health department bulletin, Jharkhand currently has six active Covid cases. As many as nine patients have recovered from the disease since January 1 this a spike in Covid cases, the Centre has launched nationwide mock drills to assess hospital preparedness and directed states to ensure adequate oxygen supply, isolation beds, ventilators, and essential drugs. Officials have claimed that most cases are mild and managed under home review meetings were held on June 2 and 3, led by Dr Sunita Sharma, Director General of Health Services, to assess the Covid-19 situation and review the country's preparedness InMust Watch


News18
an hour ago
- News18
Bharat Biotech's Nasal Vaccine 'Can Adapt' To New COVID Strains, Regulatory Nod Awaited
Last Updated: Bharat Biotech told News18 that the company's COVID-19 vaccine platforms are enabled for 'adaptation'. However, restarting production needs regulatory agency approvals. Amid rising concerns over the JN.1 COVID-19 variant, Indian vaccine maker Bharat Biotech has stated its preparedness to address the emerging variant with its 'adaptable" vaccine platforms. However, production will only restart with regulatory approval. Suchitra Ella, Managing Director of Bharat Biotech, told News18 that the company is 'actively monitoring the ongoing situation" and remains prepared to respond, emphasising the adaptability of its vaccine platforms to evolving strains. 'We remain committed to ensuring that our vaccine platforms are adaptable and ready to respond to evolving strains," she said. As of 11 June, India has recorded 7,121 active COVID-19 cases, according to the Union Health Ministry's official COVID-19 dashboard. Delhi, Gujarat, Kerala, Maharashtra, and West Bengal report the majority of these cases. Highlighting the benefits of its nasal vaccine, iNCOVACC, Ella told News18 that its intranasal COVID-19 vaccine offers targeted upper respiratory tract protection, ease of administration without needles, and adaptability to circulating strains. The company affirms its proactive monitoring and preparedness: 'actively monitoring the situation and well-positioned to respond effectively if the need arises." iNCOVACC, India's first intranasal COVID-19 vaccine, is available as a booster dose for adults. Its needle-free design, with drops instilled into each nostril, eliminates the need for trained healthcare professionals for administration. Ella confirmed the adaptability of both the injectable and intranasal COVID-19 vaccine platforms. 'However, any decision to restart production is contingent upon regulatory agency approvals. We continue to work in close coordination with regulatory bodies to ensure preparedness always aligns with evolving scientific and safety standards," she explained in an emailed interview with News18. While several countries recommend booster doses for high-risk and vulnerable groups, experts in India have not yet issued such a recommendation. 'Booster doses have been recommended in several countries for high-risk and vulnerable populations. Booster doses in our country are subject to approval from national regulatory agencies." Ella clarified that COVID-19 vaccine production would only recommence if directed by the national regulatory body. She also revealed the extent of vaccine wastage due to declining demand: 'As of early 2022, production of COVAXIN was paused in response to reduced demand and the cancellation of issued purchase orders. Subsequently, we proceeded with the destruction of around 20 crore doses of bulk and almost 5 crore doses of vaccines in vials." A senior health ministry source informed News18 that the recent rise in COVID-19 cases is no cause for panic, likening the current trend to seasonal influenza. While no immediate vaccination is necessary, basic precautions are advised, especially for those exhibiting symptoms. 'Wear a mask if you have a cough or cold, and request those around you to do the same, and people with co-morbidities like diabetes or kidney disease should remain particularly cautious during this period." Although booster shots may not be currently necessary in India, given the mild, influenza-like illness caused by current variants, the preparedness of Indian vaccine companies and their adaptable platforms demonstrate the nation's capacity for rapid response should more severe COVID-19 variants or other pathogens emerge.